Factor Viii 1200IU Human Von Willebrand Factor

This tender, originating from Jordan, concerns the procurement of 'Factor VIII 1200 IU Human Von Willebrand Factor'. This indicates a requirement for a specific, high-value pharmaceutical product used in the treatment of bleeding disorders, particularly hemophilia A and von Willebrand disease. The contracting authority is likely a governmental health ministry, a national blood bank, or a major hospital procuring specialized medications. The tender seeks a reliable supply of this critical medication, ensuring it meets stringent quality, safety, and efficacy standards. Typical requirements for pharmaceutical tenders include adherence to Good Manufacturing Practices (GMP), provision of Certificates of Analysis (CoA), specific packaging and storage conditions (e.g., cold chain requirements), expiry dating, and regulatory approval from the Jordan Food and Drug Administration (JFDA). Bidders must be licensed pharmaceutical manufacturers or distributors with the capacity to supply the specified quantity within the required timeframe. The evaluation will focus on product quality, compliance, supplier credentials, and pricing.